Cargando…
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
BACKGROUND: The efficacy of oxaliplatin-based chemotherapy combined with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) remains controversial in metastatic colorectal cancer (mCRC). This meta-analysis aims to estimate the effect of adding panitumumab or cetuximab to oxaliplat...
Autores principales: | Chen, Datian, Li, Li, Zhang, Xiang, Gao, Guangyi, Shen, Lili, Hu, Jing, Yang, Mi, Liu, Baorui, Qian, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882422/ https://www.ncbi.nlm.nih.gov/pubmed/29517682 http://dx.doi.org/10.1097/MD.0000000000010097 |
Ejemplares similares
-
Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis
por: Chen, Datian, et al.
Publicado: (2018) -
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
por: Chen, Datian, et al.
Publicado: (2019) -
Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report
por: Wang, Danping, et al.
Publicado: (2019) -
Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports
por: Fang, Szu-Yun, et al.
Publicado: (2019) -
First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)